Jazz Pharmaceuticals (NASDAQ:JAZZ) Director Bruce Cozadd Sells 6,000 Shares

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Director Bruce Cozadd sold 6,000 shares of the business’s stock in a transaction on Monday, August 3rd. The shares were sold at an average price of $252.98, for a total transaction of $1,517,880.00. Following the sale, the director directly owned 360,682 shares in the company, valued at approximately $91,245,332.36. This trade represents a 1.64% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Jazz Pharmaceuticals Stock Performance

Shares of Jazz Pharmaceuticals stock opened at $261.57 on Thursday. The stock has a market cap of $16.98 billion, a PE ratio of 18.04, a price-to-earnings-growth ratio of 0.23 and a beta of 0.32. The business has a fifty day simple moving average of $240.46 and a 200-day simple moving average of $208.57. The company has a quick ratio of 1.85, a current ratio of 1.78 and a debt-to-equity ratio of 0.69. Jazz Pharmaceuticals PLC has a 12 month low of $105.00 and a 12 month high of $265.05.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its quarterly earnings results on Monday, August 3rd. The specialty pharmaceutical company reported $5.71 earnings per share for the quarter, missing analysts’ consensus estimates of $6.18 by ($0.47). The business had revenue of $1.21 billion for the quarter, compared to analysts’ expectations of $1.11 billion. Jazz Pharmaceuticals had a net margin of 20.45% and a return on equity of 33.97%. The business’s quarterly revenue was up 15.5% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($8.25) EPS. On average, sell-side analysts anticipate that Jazz Pharmaceuticals PLC will post 21.9 EPS for the current fiscal year.

Institutional Investors Weigh In On Jazz Pharmaceuticals

Several large investors have recently made changes to their positions in JAZZ. Cardinal Capital Management lifted its stake in Jazz Pharmaceuticals by 0.5% in the 4th quarter. Cardinal Capital Management now owns 14,538 shares of the specialty pharmaceutical company’s stock valued at $2,471,000 after purchasing an additional 66 shares during the last quarter. Bessemer Group Inc. increased its position in Jazz Pharmaceuticals by 0.3% during the first quarter. Bessemer Group Inc. now owns 22,362 shares of the specialty pharmaceutical company’s stock worth $4,228,000 after buying an additional 73 shares during the last quarter. UMB Bank n.a. increased its position in Jazz Pharmaceuticals by 12.6% during the fourth quarter. UMB Bank n.a. now owns 725 shares of the specialty pharmaceutical company’s stock worth $123,000 after buying an additional 81 shares during the last quarter. Pinnacle Associates Ltd. raised its stake in Jazz Pharmaceuticals by 0.7% in the fourth quarter. Pinnacle Associates Ltd. now owns 11,203 shares of the specialty pharmaceutical company’s stock valued at $1,905,000 after buying an additional 83 shares during the period. Finally, Fifth Third Wealth Advisors LLC raised its stake in Jazz Pharmaceuticals by 4.4% in the first quarter. Fifth Third Wealth Advisors LLC now owns 1,996 shares of the specialty pharmaceutical company’s stock valued at $377,000 after buying an additional 85 shares during the period. Institutional investors own 89.14% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on JAZZ shares. JPMorgan Chase & Co. upped their target price on Jazz Pharmaceuticals from $265.00 to $276.00 and gave the company an “overweight” rating in a report on Tuesday. TD Cowen boosted their price objective on shares of Jazz Pharmaceuticals from $275.00 to $300.00 and gave the company a “buy” rating in a research report on Tuesday. Leerink Partners upped their price objective on shares of Jazz Pharmaceuticals from $215.00 to $225.00 and gave the company an “outperform” rating in a research note on Wednesday, April 22nd. Barclays increased their target price on shares of Jazz Pharmaceuticals from $260.00 to $270.00 and gave the stock an “overweight” rating in a research report on Tuesday. Finally, Stifel Nicolaus set a $275.00 target price on shares of Jazz Pharmaceuticals in a research note on Tuesday. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $272.74.

Key Headlines Impacting Jazz Pharmaceuticals

Here are the key news stories impacting Jazz Pharmaceuticals this week:

• Positive Sentiment: Jazz reported second-quarter revenue of $1.21 billion, ahead of the $1.11 billion consensus estimate and up 15.5% year over year. Management raised its 2026 revenue forecast to $4.60 billion-$4.75 billion, citing strength in its oncology and neuroscience businesses. JAZZ Q2 Earnings Miss, Sales Beat, Stock Jumps on Raised 2026 View
• Positive Sentiment: The company’s oxybate franchise, led by Xywav, continues to grow at a double-digit rate despite the launch of generic Xyrem, easing concerns about generic competition and supporting the improved guidance. Jazz Pharmaceuticals’ Re-Rating Story Has Legs
• Positive Sentiment: Multiple analysts raised their price targets following the results. Needham lifted its target to $292 and maintained a buy rating, while Morgan Stanley and Robert W. Baird raised targets to $280 with overweight and outperform ratings, respectively. JPMorgan also raised its target to $276 and maintained overweight ratings. Needham Raises Jazz Pharmaceuticals Price Target
• Positive Sentiment: Investors are also watching zanidatamab, marketed as Ziihera. A potential first-line gastroesophageal adenocarcinoma approval, with an FDA decision expected August 25, could create a significant new revenue stream and accelerate growth. Jazz Forecasts 2026 Revenue Ahead of Zanidatamab FDA Decision
• Neutral Sentiment: Second-quarter adjusted EPS was $5.71, below the $6.18 consensus estimate. The revenue beat and raised outlook outweighed the earnings miss in the market’s initial reaction, but profitability remains an area to monitor.
• Negative Sentiment: Jazz said it will withdraw Zepzelca from the FDA’s accelerated-approval pathway for second-line small-cell lung cancer, removing a potential regulatory catalyst and highlighting pressure on that product. Jazz to Withdraw Zepzelca FDA Application
• Negative Sentiment: Director Bruce C. Cozadd sold 6,000 shares worth approximately $1.52 million under a pre-arranged Rule 10b5-1 plan. Because the sale reduced his holdings by only 1.64% and was planned in advance, it is a limited negative signal rather than a clear change in insider conviction. Jazz Pharmaceuticals Insider Transaction Filing

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.